Long‐term study of re‐infection following successful eradication of <i>Helicobacter pylori</i> infection

Cameron, Ewen; Bell, G. D.; Baldwin, Lynette; Powell, K.; Williams, Simon G.

doi:10.1111/j.1365-2036.2006.02899.x

Cited by 25 publications

(22 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, the published reinfection rate of H. pylori varies substantially from 0.4% in the United Kingdom to 13% in Bangladesh (45)(46)(47). Our model confirms that chemoprevention is the dominant strategy in developed countries, where the transmission of H. pylori is low but cost of endoscopy is usually high.…”

Section: Discussionsupporting

confidence: 69%

Cost-effectiveness Analysis between Primary and Secondary Preventive Strategies for Gastric Cancer

Lee¹,

Lin²,

Wu³

et al. 2007

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Objective: The present study is done to assess the relative cost-effectiveness, optimal initial age, and interscreening interval between primary and secondary prevention strategies for gastric cancer. Methods: Base-case estimates, including variables of natural history, efficacy of intervention, and relevant cost, were derived from two preventive programs targeting a highrisk population. Cost-effectiveness was compared between chemoprevention with 13 C urea breath testing followed by Helicobacter pylori (H. pylori) eradication and high-risk surveillance based on serum pepsinogen measurement and confirmed by endoscopy. The main outcome measure was cost per life-year gained with a 3% annual discount rate. Results: The incremental cost-effectiveness ratio (ICER) for once-only chemoprevention at age 30 years versus no screening was U.S. $17,044 per life-year gained. Eradication of H. pylori at later age or with a periodic scheme yielded a less favorable result. Annual high-risk screening at age of 50 years versus no screening resulted in an ICER of U.S. $29,741 per life-year gained. The ICERs of surveillance did not substantially vary with different initial ages or interscreening intervals. Chemoprevention could be dominated by high-risk surveillance when the initial age was older than 44 years. Otherwise, chemoprevention was more costeffective than high-risk surveillance, either at ceiling ratios of U.S. $15,762 or up to U.S. $50,000. The relative costeffectiveness was most sensitive to the infection rate of H. pylori and proportion of early gastric cancer in all detectable cases. Conclusions: Early H. pylori eradication once in lifetime seems more cost-effective than surveillance strategy. However, the choice is still subject to the risk of infection, detectability of early gastric cancer, and timing of intervention. (Cancer Epidemiol Biomarkers Prev 2007;16(5):875 -85)

show abstract

Section: Discussionsupporting

confidence: 69%

Cost-effectiveness Analysis between Primary and Secondary Preventive Strategies for Gastric Cancer

Lee¹,

Lin²,

Wu³

et al. 2007

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

“…Gastroscopic reports and H. pylori infection status were not entered into the NHIRD. Cirrhotic patients have a higher possibility of an initial peptic ulcer diagnosis without concurrent H. pylori infection and a lower true H. pylori reinfection rate . Therefore, we compared only the early and late H. pylori eradication after excluded anti‐secretory therapy without H. pylori eradication to minimize these limitations.…”

Section: Discussionmentioning

confidence: 99%

“…Cameron et al 18 reported an H. pylori reinfection rate of approximately 0.4% per year. In our study the results for cirrhotic patients in the early and late H. pylori eradication groups indicated that H. pylori infection was present in the stomach before the eradication therapy was initiated.…”

Section: Discussionmentioning

confidence: 99%

Early Helicobacter pylori eradication is associated with a reduced risk of recurrent peptic ulcers in cirrhotic patients

Chang

2014

J of Digest Diseases

View full text Add to dashboard Cite

show abstract

“…Reinfection is defined as an infection with a new strain of H. pylori that is different from the original strain after complete eradication, while recrudescence is a relapse of original strain, which was temporarily suppressed by eradication therapy [14,15]. The recurrence rates of H. pylori decrease with time and decline sharply after the first year, and beyond the first year, recurrence rates come close to the rate of natural acquisition of H. pylori infection in adulthood [14,16,17].…”

Section: Discussionmentioning

confidence: 99%

Long-term follow up Helicobacter Pylori reinfection rate after second-line treatment: bismuth-containing quadruple therapy versus moxifloxacin-based triple therapy

Kim

et al. 2013

BMC Gastroenterol

View full text Add to dashboard Cite

BackgroundThe increasing trend of antibiotic resistance requires effective second-line Helicobacter pylori (H. pylori) treatment in high prevalence area of H. pylori. The aim of our study was to evaluate the reinfection rate of H. pylori after second-line treatment that would determine the long-term follow up effect of the rescue therapy.MethodsA total of 648 patients who had failed previous H. pylori eradication on standard triple therapy were randomized into two regimens: 1, esomeprazole (20 mg b.i.d), tripotassium dicitrate bismuthate (300 mg q.i.d), metronidazole (500 mg t.i.d), and tetracycline (500 mg q.i.d) (EBMT) or 2, moxifloxacin (400 mg q.d.), esomeprazole (20 mg b.i.d), and amoxicillin (1000 mg b.i.d.) (MEA). At four weeks after completion of eradication therapy, H. pylori tests were performed with 13C urea breath test or invasive tests. In patients who maintained continuous H. pylori negativity for the first year after eradication therapy, H. pylori status was assessed every year. For the evaluation of risk factors of reinfection, gender, age, clinical diagnosis, histological atrophic gastritis or intestinal metaplasia were analyzed.ResultsThe recrudescence rate of the EBMT was 1.7% and of the MEA group 3.3% (p = 0.67). The annual reinfection rate of H. pylori of EBMT was found to be 4.45% and the MEA group 6.46%. Univariate analysis (Log-rank test) showed no association with any clinical risk factor for reinfection.ConclusionsThe long-term reinfection rate of H. pylori stayed low in both of bismuth-containing quadruple therapy and moxifloxacin-based triple therapy; thus reinfection cannot affect the choice of second-line treatment.Trial registrationClinical Trial Registration Number NCT01792700

show abstract

Long‐term study of re‐infection following successful eradication of Helicobacter pylori infection

Cited by 25 publications

References 17 publications

Cost-effectiveness Analysis between Primary and Secondary Preventive Strategies for Gastric Cancer

Cost-effectiveness Analysis between Primary and Secondary Preventive Strategies for Gastric Cancer

Early Helicobacter pylori eradication is associated with a reduced risk of recurrent peptic ulcers in cirrhotic patients

Long-term follow up Helicobacter Pylori reinfection rate after second-line treatment: bismuth-containing quadruple therapy versus moxifloxacin-based triple therapy

Contact Info

Product

Resources

About